Frontiers in transplantation · 2026
Outcomes of allogeneic hematopoietic cell transplantation in patients with carbapenem-resistant organisms infection: a propensity score-matched analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yaseen Abeer, Mubaydeen Teeba, Al-Qaraleh Hazem, Otoom Ahmad, Shaban Shadee, Mesmar Hazim, Alomoush Albatoul, Da'Na Waleed, Halahleh Khalid, Abu Jazar Husam, Saadeh Salwa, Ma'koseh Mohammad, Shamieh Abdulrahman, Kullab Susan, Abu Ata Osama, Jarrah Joud, Abdel Rahman Zaid
Аннотация
BACKGROUND: Carbapenem-resistant organisms (CRO) cause significant morbidity and mortality, with a rising incidence worldwide. Immunosuppression, prolonged hospitalization, and extensive use of broad-spectrum antibiotics make allogeneic hematopoietic cell transplant (alloHCT) recipients particularly susceptible. This study evaluated the impact of peri-transplant CRO infections on alloHCT outcomes.
METHODS: We conducted a retrospective analysis of adult alloHCT recipients between 2015 and 2024. CRO infection was defined as occurring within 12 months of alloHCT. Using 1:3 propensity score matching, patients with CRO were matched to controls by age, sex, year of transplant, stem cell source, donor type, and diagnosis. Overall survival (OS) and non-relapse mortality (NRM) were analyzed using Kaplan-Meier methods and Cox proportional hazards models.
RESULTS: A total of 171 patients were included: 43 with CRO and 128 controls; 53.4% of CRO cases occurred in the last 3 years. Median age was 35 years, 66.7% were male, and 89.5% underwent transplant for malignant disease. Matched-related donors were used in 79.5%, peripheral blood stem cells in 88.3%, and myeloablative conditioning in 70.2%. Median follow-up was 27 months. CRO patients had higher ICU admission rates (30.2% vs. 17.2%, p = 0.067) and lower 1-year OS (46.5% vs. 72.7%, p = 0.002). On multivariate analysis, CRO infection was independently associated with worse OS, while engraftment predicted improved OS and lower NRM.
CONCLUSIONS: CRO infections remain an increasing challenge in alloHCT and are associated with higher ICU admission, increased NRM, and inferior survival, highlighting the need for improved prevention and management strategies.
METHODS: We conducted a retrospective analysis of adult alloHCT recipients between 2015 and 2024. CRO infection was defined as occurring within 12 months of alloHCT. Using 1:3 propensity score matching, patients with CRO were matched to controls by age, sex, year of transplant, stem cell source, donor type, and diagnosis. Overall survival (OS) and non-relapse mortality (NRM) were analyzed using Kaplan-Meier methods and Cox proportional hazards models.
RESULTS: A total of 171 patients were included: 43 with CRO and 128 controls; 53.4% of CRO cases occurred in the last 3 years. Median age was 35 years, 66.7% were male, and 89.5% underwent transplant for malignant disease. Matched-related donors were used in 79.5%, peripheral blood stem cells in 88.3%, and myeloablative conditioning in 70.2%. Median follow-up was 27 months. CRO patients had higher ICU admission rates (30.2% vs. 17.2%, p = 0.067) and lower 1-year OS (46.5% vs. 72.7%, p = 0.002). On multivariate analysis, CRO infection was independently associated with worse OS, while engraftment predicted improved OS and lower NRM.
CONCLUSIONS: CRO infections remain an increasing challenge in alloHCT and are associated with higher ICU admission, increased NRM, and inferior survival, highlighting the need for improved prevention and management strategies.